Phase I study of carboplatin, docetaxel and irinotecan with recombinant human granulocyte colony stimulating factor support in patients with advanced non-small cell lung cancer

Anti-Cancer Drugs

Volumn 11, Issue 10, 2000, Pages 821-824

  Fujita, Akihisa ^a   Takabatake, Hirotsugu ^a   Tagaki, Shigeru ^a   Sekine, Kyuhichiro ^a  

^a Minami ichijo Hospital   (Japan)

Author keywords

Docetaxel; Irinotecan; Non small cell lung cancer; Phase I study

Indexed keywords

CARBOPLATIN; DOCETAXEL; IRINOTECAN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADOLESCENT; ADULT; ADVANCED CANCER; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG TOLERABILITY; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; LEUKOPENIA; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; TAXOIDS;

EID: 0033636899     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200011000-00005     Document Type: Article

References (12)

1. Phase II trial of docetaxel in previously untreated advanced non-small-cell lung cancer: A Japanese Cooperative Study
2. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer
3. Use of docetaxel and carboplatin for patients with non-small-cell lung cancer
4. A phase I clinical and pharmacological study of a carboplatin and irinotecan regimen combined with recombinant human granulocyte-colony stimulating factor in the treatment of patients with advanced nonsmall cell lung carcinoma
5. Phase I study of docetaxel (DOC) and irinotecan (CPT-11) for previously untreated advanced non-small cell lung cancer (NSCLC)
6. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria
7. CPT-11 in combination with cisplatin for advanced non-small-cell lung cancer
8. Phase I study of cisplatin, ifosfamide and irinotecan with rhG-CSF support in advanced non-small cell lung cancer
9. Phase I trial of docetaxel and cisplatin in previously untreated patients with advanced non-small-cell lung cancer
10. A phase II study of combination of CPT-11 and cisplatin for advanced nonsmall cell lung cancer
11. Docetaxel: Meeting the challenge of nonsmall cell lung cancer management